LY3549492
Sponsors
Eli Lilly and Company
Conditions
Diabetes Mellitus, Type 2HealthyHealthy MaleObesityOverweightType 2 DiabetesType 2 Diabetes Mellitus (T2D)
Phase 1
A Study of LY3549492 in Healthy Participants
CompletedNCT04758234
Start: 2021-02-22End: 2022-01-10Updated: 2022-02-09
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT05327595
Start: 2022-05-09End: 2024-04-22Updated: 2024-05-30
A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants
CompletedNCT06194500
Start: 2024-01-03End: 2024-02-15Updated: 2024-03-28
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
CompletedNCT06869018
Start: 2025-05-07End: 2026-03-02Updated: 2026-03-20
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
CompletedNCT07073170
Start: 2025-07-25End: 2026-01-27Updated: 2026-03-03
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
CompletedNCT07232732
Start: 2025-10-27End: 2026-07-16Updated: 2026-08-24
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RecruitingNCT06143956
Start: 2023-11-17End: 2028-02-01Target: 1481Updated: 2026-09-08
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
CompletedNCT06683508
Start: 2024-11-13End: 2026-05-04Updated: 2026-05-13
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
TerminatedNCT07030868
Start: 2025-06-19End: 2025-07-29Updated: 2026-08-31
A Study of LY3549492 in Healthy Weight Adult Participants
TerminatedNCT07085468
Start: 2025-07-21End: 2025-08-14Updated: 2025-08-29